Noom Med Offers Employers a Cost-Effective Solution for Weight Loss Drugs

From brochures in doctors’ offices to the front pages of tabloids, mentions of trending weight loss medications are inescapable. Employers are seeing a growing demand for GLP1-s, like Ozempic, Wegovy, and Mounjaro, as more Employees seek alternative solutions to lose weight. Now, employers are scrambling to understand which employees qualify for this type of medication,how to manage the cost, or whether to cover GLP-1 medications at all 

With this growing commercial need, Noom for Work launched Noom Med, a clinical obesity management solution that combines evidence-based obesity care with an award-winning behavior change program to help members achieve sustained weight loss while lowering employer costs. GLP-1s have revolutionized obesity treatment, but medication alone isn’t enough to sustain weight loss — a point of contention that causes employers to hesitate in offering these types of weight loss medications to employees. 

“GLP-1s can be taken for years — and research shows that if you stop the medication, employees will gain the weight back. So employers are terrified, and looking to get the most bang for their buck,” said Dr. Linda Anegawa, an obesity medicine specialist and the chief medical officer of weight loss app Noom.* 

Noom’s program tackles this problem head-on by anchoring clinical care with behavior change to give employees the best chance for long-term success. It uses a stepped care model that pairs a broad spectrum of care with personalized support that’s tailored to each member’s unique biology and lifestyle. Members are guided to the right care at the right time — only stepping up to medication to match the appropriate level of investment for the best health outcome.

Noom has already helped members lead healthier lives while reducing unnecessary spend and costs for employers. They’ve reported: 

• 45% of Noom Med patients are never issued a GLP-1
• 6x more weight loss achieved at 12 months by pairing Noom’s behavior change with Saxenda versus Saxenda alone²
• 3.1x ROI by investing in Noom Med versus GLP-1s without cost control³

Learn more about Noom Med and how it can help your employees start leading healthier lives. 

*EBN: Employees want weight loss drugs Ozempic and Wegovy. Can employers afford them? By Stephanie Schomer

¹ Noom internal ROI analysis.

² Feasibility Assessment of Weight Loss Outcomes of Saxenda Users vs. Non-Users Enrolled in the Noom Program, 2018–2021.

³ Noom internal ROI analysis.